Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease

Study Overview
=================
Brief Summary
-----------------
We aimed to evaluate the hypothalamus-pituitary-adrenal axis in autosomal dominant polycystic kidney disease (ADPKD) patients. Twenty two ADPKD patients and 27 healthy subjects were enrolled.

Detailed Description
-----------------
CONTEXT: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and extrarenal manifestations may be observed in many organ systems. Hypothalamus-pituitary-adrenal axis in patients with ADPKD was not evaluated extensively. OBJECTIVE: We aimed to evaluate the hypothalamus-pituitary-adrenal axis in ADPKD patients. METHODS: Twenty two ADPKD patients and 27 healthy subjects were enrolled. Basal dehydroepiandrosterone-sulfate (DHEAS) levels and cortisol and dehydroepiandrosterone responses to low dose short adrenocorticotropin stimulation test were assessed. Correlation analyses of these parameters with glomerular filtration rates, renal volumes and pain characteristics in patients with ADPKD were done.

Official Title
-----------------
Assessment of Adrenal Functions in Patients With Autosomal Dominant Polycystic Kidney Disease

Conditions
-----------------
Autosomal Dominant Polycystic Kidney Disease

Intervention / Treatment
-----------------
* Drug: Tetracosactin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy subjects Diagnosis of autosomal dominant polycystic kidney disease Exclusion Criteria: A glomerular filtration rate below 60 ml/min History of recent major surgery Systemic infections with fever Significant hirsutism (Ferriman Gallwey score≥8) Congenital adrenal hyperplasia Late onset congenital adrenal hyperplasia Systemic corticosteroid use (including previous use) Topical corticosteroid use Menstrual irregularity History of thromboembolism Uncontrolled diabetes or hypertension History of psychosis Pregnancy Lactation History of hypersensitivity to tetracosactin

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 56 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Patients with autosomal dominant polycystic kidney disease | Drug: Tetracosactin<br>* 1 microgram tetracosactin, intravenous injection, once for the test<br>* Other names: Synacthen;|
| Active Comparator: 2<br>Healthy subjects | Drug: Tetracosactin<br>* 1 microgram tetracosactin, intravenous injection, once for the test<br>* Other names: Synacthen;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inadequate response to tetracosactin infusion |  | 30 and 60 minutes after the drug is administered | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Autosomal dominant polycystic kidney disease, Adrenal functions, Renal volume, Glomerular filtration rate, Adrenal Cortex Function Tests